#USA #Carlsbad #Active Motif #Arima Genomics #3D Genomics

Active Motif and Arima Genomics Form Exclusive Global Partnership

In a significant move for the genomic research landscape, Active Motif, a leading provider of epigenetics and multiomics solutions, has officially announced an exclusive global distribution agreement with Arima Genomics, a forefront player in cancer diagnostics specializing in advanced 3D genomics and Hi-C sequencing technology. This partnership is poised to expand both companies' capabilities and offerings in groundbreaking genomic research.

The newly established agreement positions Active Motif as the exclusive global distributor of Arima’s Hi-C products and services specifically for research applications. Meanwhile, Arima is ramping up its focus on its clinical diagnostics platform, “Aventa.” This strategic alliance exemplifies a shared dedication to advancing genomic technologies that enable researchers to comprehend how genomic structure influences gene regulation, cell function, and disease biology.

With the rapid evolution of genomics research, transitioning beyond mere sequence-based analyses, 3D genomic mapping technologies like Hi-C have become essential tools. These advancements assist in understanding chromatin organization, structural variations, and regulatory mechanisms at a genomic-wide scale. The implications are profound, with particular significance in areas such as cancer research, neuroscience, developmental biology, rare diseases, and precision medicine, becoming increasingly vital.

Joe Fernandez, Chairman and Founder of Active Motif, remarked, “This agreement solidifies Active Motif’s role as a leader in integrated multiomics solutions. Researchers are increasingly pursuing a comprehensive understanding of genomic function that combines chromatin accessibility, transcription factor binding, epigenetic regulation, gene expression, and genome architecture. By incorporating Arima's industry-leading Hi-C technology into our portfolio, we enhance our ability to support customers with end-to-end solutions that address some of today's most critical biological questions.”

As part of the agreement, Active Motif will significantly enhance its already growing portfolio of genomics and epigenomics technologies. This encompasses services and products essential for chromatin profiling, transcriptional regulation, and next-generation sequencing applications. Integrating Hi-C technology will further bolster Active Motif’s capabilities to address burgeoning markets in spatial genomics and 3D biology while opening up new opportunities for integrated multiomic workflows.

Dr. Tom Willis, CEO of Arima Genomics, highlighted the significance of this partnership: “Arima is focusing on the substantial future opportunities within our clinical diagnostics platform ‘Aventa,’ where we connect DNA sequence and structure to uncover cancer-driving alterations in routine FFPE tumor samples. This agreement allows us to align our research-focused Hi-C technologies with the highly complementary offerings of Active Motif, whose global commercial infrastructure, scientific expertise, and longstanding relationships within the research community are invaluable.”

The exclusive distribution framework marries Arima's technological leadership in 3D genomics with Active Motif's established global distribution network and technical support capabilities, ensuring broader access for academic, pharmaceutical, biotechnology, and clinical research institutions.

The agreement takes effect immediately, making Arima’s Hi-C products and services available globally through Active Motif for research applications as they look to provide researchers with innovative tools to drive advancements in understanding health and disease.

About Active Motif

Active Motif stands out in the fields of epigenetics, genomics, and multiomics by supplying researchers with solutions to explore gene regulation, chromatin biology, and mechanisms of disease. With innovative products, services, and scientific expertise, Active Motif empowers scientists worldwide to gain insights that benefit human health.

About Arima Genomics

Arima Genomics is redefining cancer diagnostics by integrating DNA sequence and structure. Building on its leading role in 3D genomics and Hi-C sequencing technology, Arima develops clinical tests that reveal cancer-driving changes often overlooked or only partially characterized by conventional approaches. Through its clinical testing brand “Aventa,” Arima offers tests for solid tumors and lymphomas in its CLIA-certified laboratory in Orlando, Florida. Learn more at www.arimagenomics.com and aventatest.com.